Enhanced Hypertonic Pharmaceutical Compositions for Ototoxicity Prevention

This invention provides improved hypertonic pharmaceutical compositions and systems for preventing platinum-induced ototoxicity, offering enhanced safety, efficacy, and convenience for cancer patients.

The original patent (Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent) addressed the need for compositions to mitigate ototoxicity associated with platinum-based antineoplastic agents. However, the original compositions had limitations, such as restricted osmolarity ranges and limited administration options. The new inventive concept overcomes these limitations by introducing controlled release devices, non-invasive delivery routes, and pH-adjusting agents, providing more effective and convenient prevention of ototoxicity.

The new inventive concept comprises hypertonic pharmaceutical compositions with calculated osmolarities between 2,000-4,000 mOsm/L, containing 1M-2M of an anti-platinum chemoprotectant agent, a gelling agent, and a pH-adjusting agent. These compositions are designed for administration via controlled release devices or non-invasive delivery routes, ensuring a more consistent and effective delivery of the chemoprotectant agent. Additionally, the pH of the composition is adjusted to a range of 6.0-7.5, enhancing the stability and efficacy of the agent. The inventive concept also includes systems for monitoring hearing thresholds and preventing hearing loss in patients receiving platinum-based antineoplastic agents.

The new claims introduce novel features, such as controlled release devices, non-invasive delivery routes, and pH-adjusting agents, which are not present in the original patent. These features provide a significant improvement in the prevention of ototoxicity, making the new inventive concept non-obvious and novel compared to the original patent.

Alternative embodiments of the inventive concept could include the use of different gelling agents, pH-adjusting agents, or chemoprotectant agents. Additionally, the compositions could be adapted for administration via other routes, such as injectable or implantable devices. The systems for monitoring hearing thresholds could also be modified to incorporate different types of sensors or monitoring devices.

The enhanced hypertonic pharmaceutical compositions and systems have significant commercial potential in the oncology market, providing a safer and more effective solution for preventing ototoxicity in cancer patients. The market for these compositions and systems is expected to grow as the incidence of cancer increases and the need for effective chemoprotectant agents becomes more pressing.